Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors
Received 29 January 2020
Accepted for publication 13 May 2020
Published 16 June 2020 Volume 2020:12 Pages 4585—4593
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication: Dr Yong Teng
Keitaro Shimozaki,1 Yasutaka Sukawa,1 Noriko Beppu,2 Isao Kurihara,3 Shigeaki Suzuki,4 Ryuichi Mizuno,5 Takeru Funakoshi,6 Shinnosuke Ikemura,7,8 Kai Tsugaru,1 Kazuhiro Togasaki,1 Kenta Kawasaki,1 Kenro Hirata,1 Hideyuki Hayashi,8 Yasuo Hamamoto,8 Hiromasa Takaishi,8 Takanori Kanai1
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; 2Department of Pharmacy, Keio University Hospital, Tokyo, Japan; 3Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; 4Department of Neurology, Keio University School of Medicine, Tokyo, Japan; 5Department of Urology, Keio University School of Medicine, Tokyo, Japan; 6Department of Dermatology, Keio University School of Medicine, Tokyo, Japan; 7Division of Pulmonary Medicine, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan; 8Keio Cancer Center, Keio University School of Medicine, Tokyo, Japan
Correspondence: Yasutaka Sukawa Tel +81-3-3353-1211
Purpose: Immune checkpoint inhibitors (ICIs) have been approved for various types of cancer; however, they cause a broad spectrum of immune-related adverse events (irAEs). The association between the development of irAEs and the clinical benefit remains uncertain. We aimed to evaluate the association of irAEs and the treatment efficacy in real-world practice.
Patients and Methods: We conducted a retrospective study on patients with recurrent or metastatic non-small-cell lung cancer, malignant melanoma, renal cell carcinoma, or gastric cancer who received anti-PD-1/PD-L1 antibodies (nivolumab, pembrolizumab, or atezolizumab) at the Keio University Hospital between September 2014 and January 2019. We recorded treatment-related AEs from medical records and graded them using the Common Terminology Criteria for Adverse Events version 4. We performed an overall survival (OS) analysis using a Cox proportional hazards model and the shared frailty model.
Results: Of 212 patients eligible for this study, 108 experienced irAEs and 42 developed multiple irAEs. The median OS was significantly longer in the irAEs than in the no-irAE group (28.1 months vs 12.7 months; hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.33– 0.73; P = 0.0004). Moreover, the OS of patients with multiple irAEs was significantly longer than that of patients with a single irAE (42.3 months vs 18.8 months; HR, 0.473; 95% CI, 0.346– 0.647; P < 0.0001).
Conclusion: Our single-center retrospective study revealed a significant tendency associating the development of multiple irAEs with favorable prognoses.
Keywords: immune checkpoint inhibitors, programmed cell death 1, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]